TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34788455

Group type: EXPERIMENTAL
Intervention: Childhood ALL survivors
Number of subjects: 507

Group type: COMPARATOR
Intervention: General population controls
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Partners of male survivors
Number of subjects: 507

Group type: COMPARATOR
Intervention: Partners of general population controls
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Female survivors (age at diagnosis 10-17 years)
Number of subjects: 507
Study: 34788488

Group type: EXPERIMENTAL
Intervention: Rotarix
Number of subjects: 228233

Group type: EXPERIMENTAL
Intervention: RotaTeq
Number of subjects: 228233

Group type: EXPERIMENTAL
Intervention: Rotasiil
Number of subjects: 228233

Group type: EXPERIMENTAL
Intervention: Rotavac
Number of subjects: 228233
Study: 34788507

Group type: EXPERIMENTAL
Intervention: SPK-8011 (AAV vector)
Number of subjects: 18
Study: 34788506

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with an α-L-iduronidase (IDUA)-encoding lentiviral vector after myeloablative conditioning
Number of subjects: 8
Study: 34788603

Group type: EXPERIMENTAL
Intervention: Large SOVi group
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Medium SOVi group
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Small SOVi group
Number of subjects: 1554
Study: 34788804

Group type: EXPERIMENTAL
Intervention: Multimorbidity index (9 chronic diseases)
Number of subjects: 3842

Group type: EXPERIMENTAL
Intervention: Frailty index (FI) based on deficit accumulation
Number of subjects: 3842
Study: 34789141

Group type: EXPERIMENTAL
Intervention: 40g starch from white wheat bread
Number of subjects: 1764

Group type: EXPERIMENTAL
Intervention: 80g starch from white wheat bread
Number of subjects: 1764

Group type: EXPERIMENTAL
Intervention: High starch intake
Number of subjects: 1764

Group type: EXPERIMENTAL
Intervention: Low starch intake
Number of subjects: 1764

Group type: COMPARATOR
Intervention: Control group (low AMY1 CN)
Number of subjects: 1764
Study: 34789156

Group type: EXPERIMENTAL
Intervention: Plasma soluble urokinase plasminogen activator receptor (suPAR) levels ≥ 14.7 ng/mL
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Clinical complications present
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: suPAR
Number of subjects: 282
Study: 34789304

Group type: COMPARATOR
Intervention: Highly malignant EEG pattern
Number of subjects: 489

Group type: COMPARATOR
Intervention: Malignant EEG pattern
Number of subjects: 489

Group type: COMPARATOR
Intervention: Background EEG frequency of predominant delta waves or undetermined
Number of subjects: 489

Group type: COMPARATOR
Intervention: Combination of highly malignant or malignant EEG pattern with background frequency of delta waves or undetermined
Number of subjects: 489
Study: 34789490

Group type: EXPERIMENTAL
Intervention: Malaria diagnosis using blood samples from participants >3 months old
Number of subjects: 2690

Group type: EXPERIMENTAL
Intervention: Serology for SARS-CoV-2 IgG antibodies introduced in 2020
Number of subjects: 2690
Study: 34789494

Group type: EXPERIMENTAL
Intervention: 10 weekly singing sessions facilitated by Breathe Arts Health Research
Number of subjects: 400

Group type: COMPARATOR
Intervention: Non-singing sessions in the community or online for 10 weeks
Number of subjects: 400
Study: 34789498

Group type: EXPERIMENTAL
Intervention: Ancestry-matched T2D genetic risk scores (GRSeur)
Number of subjects: 1513

Group type: COMPARATOR
Intervention: Ancestry-matched or cross-ancestry GRS
Number of subjects: 1513
Study: 34789774

Group type: EXPERIMENTAL
Intervention: Deep learning (DL) network for predicting early on-treatment response in mCRC.
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Size-based methodology for predicting early on-treatment response in mCRC.
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Integration of DL network with size-based methodology.
Number of subjects: 1028
Study: 34789848

Group type: EXPERIMENTAL
Intervention: Medication-free neuroimaging
Number of subjects: 2
Study: 34790142

Group type: EXPERIMENTAL
Intervention: Brief psycho-educational training program on positive emotion regulation (ER)
Number of subjects: 30
Study: 34790237

Group type: EXPERIMENTAL
Intervention: Antibiotics as adjunctive therapy to NSPT
Number of subjects: 7
Study: 34790261

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus nab-paclitaxel (GnP) as second-line chemotherapy
Number of subjects: 40
Study: 34790348

Group type: EXPERIMENTAL
Intervention: Seralutinib (inhaled), administered for 24 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo, administered for 24 weeks
Number of subjects: 80
Study: 34790371

Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg once daily) plus S-1 (40-60 mg twice daily on days 1-14)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Apatinib plus S-1
Number of subjects: 37
Study: 34790686

Group type: COMPARATOR
Intervention: Triglyceride-related markers
Number of subjects: 0
Study: 34790722

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by surgery
Number of subjects: 185

Group type: COMPARATOR
Intervention: Non-pCR group (subclassified into ypTanyN0M0, ypT0NanyM0, ypTanyNanyM0)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: pCR after nCRT
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Lymph-node status
Number of subjects: 185
Study: 34791490

Group type: EXPERIMENTAL
Intervention: Communication strategies for introducing new clinical practices
Number of subjects: 61
Study: 34791571

Group type: EXPERIMENTAL
Intervention: Plasma exchange with albumin replacement (PE-A) 5%
Number of subjects: 13
Study: 34791634

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide extended-release (TA-ER) 32 mg
Number of subjects: 292

Group type: COMPARATOR
Intervention: Conventional triamcinolone acetonide crystalline suspension (TAcs) 40 mg
Number of subjects: 292

Group type: COMPARATOR
Intervention: Saline-placebo
Number of subjects: 292
Study: 34791718

Group type: EXPERIMENTAL
Intervention: Normal CYP2B6 activity (n=64)
Number of subjects: 173
Study: 34791755

Group type: EXPERIMENTAL
Intervention: Novel low-dose paclitaxel-coated balloon with citrate-based excipient (Agent PCB)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Widely used paclitaxel-coated balloon with iopromide excipient (SeQuent Please PCB)
Number of subjects: 125
Study: 34791888

Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 0
Study: 34792107

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (CAPOX)
Number of subjects: 61
Study: 34792470

Group type: EXPERIMENTAL
Intervention: Primasun Sleep Apnea Program (Verily Sleep Apnea Program)
Number of subjects: 157
Study: 34792478

Group type: EXPERIMENTAL
Intervention: MB Plus Text Messaging (MB-TXT)
Number of subjects: 28
Study: 34792477

Group type: EXPERIMENTAL
Intervention: Teleassessments using a computer tablet and testing equipment shipped to participants' homes
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Teleassessments
Number of subjects: 36
Study: 34792479

Group type: EXPERIMENTAL
Intervention: OutsidePlay web-based intervention
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (Position Statement on Active Outdoor Play)
Number of subjects: 324
Study: 34792559

Group type: EXPERIMENTAL
Intervention: Nicotinamide (1000 to 3000 mg) and pyruvate (1500 to 3000 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nicotinamide and pyruvate
Number of subjects: 42
Study: 34792787

Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 9
Study: 34793256

Group type: EXPERIMENTAL
Intervention: Venetoclax (dose-escalated from 200 mg to a maximum of 800 mg daily for up to 2 years)
Number of subjects: 32
Study: 34793505

Group type: EXPERIMENTAL
Intervention: WRSs2 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WRSs3 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WRSs2 and WRSs3 vaccines
Number of subjects: 0
Study: 34793516

Group type: EXPERIMENTAL
Intervention: Aerobic fitness (AF) without adjustment for adiposity or physical activity (PA)
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Aerobic fitness (AF) with adjustment for physical activity (PA)
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Aerobic fitness (AF) with adjustment for adiposity
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Aerobic fitness (AF) with adjustment for both adiposity and physical activity (PA)
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 841
Study: 34793647

Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation (RFD)
Number of subjects: 331
Study: 34793719

Group type: EXPERIMENTAL
Intervention: Single-agent evorpacept (0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg once per week; 30 mg/kg once every other week)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Evorpacept plus pembrolizumab (200 mg every 3 weeks)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Evorpacept plus trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Evorpacept (30 mg/kg once every other week)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Evorpacept (10 mg/kg once per week)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Evorpacept plus pembrolizumab
Number of subjects: 110
Study: 34793923

Group type: EXPERIMENTAL
Intervention: Combination of plaque features (matrix, intraplaque hemorrhage [IPH], wall thickness, plaque burden) and clinical features (age, body mass index, lipid levels)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Percent diameter stenosis
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Selected predictive model including IPH and wall remodeling
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Validation dataset model
Number of subjects: 221
Study: 34793964

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34794118

Group type: EXPERIMENTAL
Intervention: Fun For Wellness intervention
Number of subjects: 461
Study: 34794172

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 2310

Group type: COMPARATOR
Intervention: Hypomethylating agents
Number of subjects: 2310

Group type: COMPARATOR
Intervention: sAML
Number of subjects: 2310

Group type: COMPARATOR
Intervention: sAML after hematologic disorder
Number of subjects: 2310
Study: 34794387

Group type: EXPERIMENTAL
Intervention: OR extubation group
Number of subjects: 438

Group type: COMPARATOR
Intervention: ICU extubation group
Number of subjects: 438
Study: 34794396

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy with liposomal irinotecan (nal-IRI), oxaliplatin (OX), and 5-fluouracil/folinic acid (FA) (NAPOX)
Number of subjects: 150
Study: 34794412

Group type: EXPERIMENTAL
Intervention: Durvalumab-containing arms
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cediranib + Olaparib
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Durvalumab + Olaparib
Number of subjects: 5
Study: 34794420

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) starting dosage 30 mg/kg/day in 6 hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 30
Study: 34794514

Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 0
Study: 34794682

Group type: EXPERIMENTAL
Intervention: Tooth extraction in kidney transplant recipients
Number of subjects: 95

Group type: COMPARATOR
Intervention: Tooth extraction in control patients (non-kidney transplant)
Number of subjects: 95
Study: 34794687

Group type: EXPERIMENTAL
Intervention: 1-month DAPT
Number of subjects: 3652

Group type: COMPARATOR
Intervention: 3-month DAPT
Number of subjects: 3652
Study: 34794987

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 40
Study: 34794989

Group type: EXPERIMENTAL
Intervention: Systemic therapy with androgen deprivation therapy (ADT) and intensification with agents such as docetaxel, abiraterone acetate, and enzalutamide.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Local cytoreductive approaches (external beam radiotherapy, cytoreductive radical prostatectomy, or minimally invasive ablative therapy) and metastases-directed therapies (metastasectomy or stereotactic ablative body radiotherapy).
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Qualitative analysis component with patients (n=15) and healthcare professionals (n=5).
Number of subjects: 300
Study: 34795005

Group type: EXPERIMENTAL
Intervention: ICI camrelizumab plus gemcitabine and oxaliplatin
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Genomic signature including 11 genes
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: High mutation load in KRAS signaling genes
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Signature wild-type subtype with favorable TME
Number of subjects: 98
Study: 34795065

Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 1894

Group type: COMPARATOR
Intervention: secukinumab 150 mg
Number of subjects: 1894
Study: 34795131

Group type: EXPERIMENTAL
Intervention: 30-minute infusion of ramucirumab
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: 60-minute infusion of ramucirumab
Number of subjects: 559
Study: 34795254

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (PD-1 blockade)
Number of subjects: 14
Study: 34795408

Group type: EXPERIMENTAL
Intervention: Pamiparib (60 mg BID, RP2D; 80 mg BID, MTD)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pamiparib in epithelial ovarian cancer (EOC) population (n=51)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pamiparib (80 mg BID)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pamiparib (dose-escalation phase)
Number of subjects: 101
Study: 34795409

Group type: EXPERIMENTAL
Intervention: Dynamic PET/computed tomography imaging
Number of subjects: 39
Study: 34795626

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0
Study: 34795635

Group type: EXPERIMENTAL
Intervention: Tap Test intervention, details not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34795661

Group type: EXPERIMENTAL
Intervention: Herpesvirus DNAemia
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: High TTV viraemia (>10,000 copies/ml)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Herpesvirus DNAemia coupled with high TTV viraemia
Number of subjects: 377
Study: 34795912

Group type: EXPERIMENTAL
Intervention: Combination pemetrexed-cisplatin chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etoposide-cisplatin chemoradiotherapy
Number of subjects: 0
Study: 34796337

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cabozantinib and nivolumab
Number of subjects: 15
Study: 34796373

Group type: EXPERIMENTAL
Intervention: Y90 glass microspheres (TheraSphere™)
Number of subjects: 115
Study: 34796395

Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Older age (per 1 year)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Lower maternal educational level (≥ high school vs. < high school)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Increased parent and self-identification of medication barriers (per 1 point)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Nonadherence
Number of subjects: 225
Study: 34796678

Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: L2-L3 VAT
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: L3-L4 VAT
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Adiponectin concentration
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Leptin concentration
Number of subjects: 1711
Study: 34796742

Group type: EXPERIMENTAL
Intervention: Patients with COPD
Number of subjects: 4791

Group type: COMPARATOR
Intervention: Patients without COPD
Number of subjects: 4791

Group type: EXPERIMENTAL
Intervention: Primary outcome
Number of subjects: 4791
Study: 34797012

Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter-defibrillator (S-ICD)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Transvenous ICD
Number of subjects: 176
Study: 34797221

Group type: EXPERIMENTAL
Intervention: 20% albumin administered at 3 mL/kg by intravenous infusion over 30 minutes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 20% albumin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Norepinephrine for hemodynamic support
Number of subjects: 15
Study: 34797307

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test in FM patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study: 34797405

Group type: COMPARATOR
Intervention: MRI findings classified as severe (Schizas C+D)
Number of subjects: 437

Group type: COMPARATOR
Intervention: MRI findings (cross-sectional area < 75 mm²)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Preoperative scores for Oswestry Disability Index, Zurich Claudication Questionnaire, and Numeric rating scale for back and leg pain
Number of subjects: 437
Study: 34797699

Group type: EXPERIMENTAL
Intervention: Ibrutinib with Rituximab (IR)
Number of subjects: 50
Study: 34797725

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 0
Study: 34797737

Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omega-6 Fatty Acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34797911

Group type: EXPERIMENTAL
Intervention: Systemic interleukin-15 (IL-15; N-803)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-15/N-803
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-15
Number of subjects: 0
Study: 34797955

Group type: EXPERIMENTAL
Intervention: Community-based mentor mothers (cMMs) intervention with ≥4 home visits up to 6 weeks postpartum
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Community-based mentor mothers (cMMs) intervention
Number of subjects: 589
Study: 34798051

Group type: EXPERIMENTAL
Intervention: Low-grade mosaic embryos
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Medium-grade mosaic embryos
Number of subjects: 484

Group type: COMPARATOR
Intervention: Euploid embryos
Number of subjects: 484
Study: 34798080

Group type: EXPERIMENTAL
Intervention: Cumulative heart rate characteristics (HRC) index
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Cumulative mean HRC score included in predictive models
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Parsimonious model including birth weight, sex, ventilatory status, and cumulative mean HRC score
Number of subjects: 598
Study: 34798334

Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 1000
Study: 34798899

Group type: EXPERIMENTAL
Intervention: Four random cervical biopsies
Number of subjects: 173

Group type: COMPARATOR
Intervention: One cervical biopsy
Number of subjects: 173
Study: 34799295

Group type: EXPERIMENTAL
Intervention: Dynamic computed tomography perfusion (CTP) with regadenoson prior to and at least 3 months after successful CTO recanalization
Number of subjects: 10
Study: 34799399

Group type: EXPERIMENTAL
Intervention: NIZ985 (0.25, 0.5, 1, 2 or 4 µg/kg subcutaneous TIW for the first 2 weeks of each 28-day cycle)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: NIZ985
Number of subjects: 14
Study: 34799400

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 937
Study: 34799430

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 701

Group type: COMPARATOR
Intervention: Usual obesity care
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Diabetes remission at 10-year follow-up
Number of subjects: 701
Study: 34799496

Group type: EXPERIMENTAL
Intervention: Surgical and nonsurgical procedures under anaesthesia
Number of subjects: 9497

Group type: EXPERIMENTAL
Intervention: Unplanned ICU admission
Number of subjects: 9497

Group type: EXPERIMENTAL
Intervention: Planned ICU admission
Number of subjects: 9497

Group type: EXPERIMENTAL
Intervention: Admission to a unit with geriatric care within 30 days after the intervention
Number of subjects: 9497

Group type: EXPERIMENTAL
Intervention: Multimorbidity
Number of subjects: 9497

Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 9497

Group type: EXPERIMENTAL
Intervention: Limited mobility
Number of subjects: 9497
Study: 34799745

Group type: EXPERIMENTAL
Intervention: Transoral incisionless fundoplication (TIF) with Medigus Ultrasonic Surgical Endostapler (MUSE)
Number of subjects: 46
Study: 34800109

Group type: EXPERIMENTAL
Intervention: Isatuximab in combination with pomalidomide plus dexamethasone
Number of subjects: 0
Study: 34800167

Group type: EXPERIMENTAL
Intervention: Myasthenia gravis patients (MG)
Number of subjects: 1660

Group type: COMPARATOR
Intervention: General population (genP)
Number of subjects: 1660
Study: 34800279

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for cardioembolic LVO (CE-LVO)
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Endovascular treatment (EVT) for other stroke subtypes
Number of subjects: 1635
Study: 34800283

Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 1321
Study: 34800495

Group type: EXPERIMENTAL
Intervention: Photobiomodulation Therapy (FBMT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Morphine consumption
Number of subjects: 9
Study: 34800678

Group type: EXPERIMENTAL
Intervention: Vibostolimab monotherapy (2.1-700 mg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Vibostolimab plus pembrolizumab (200 mg) combination therapy
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Vibostolimab plus pembrolizumab combination therapy in anti-PD-1/PD-L1-naive NSCLC
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Vibostolimab monotherapy in anti-PD-1/PD-L1-refractory NSCLC
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Vibostolimab plus pembrolizumab combination therapy in anti-PD-1/PD-L1-refractory NSCLC
Number of subjects: 76
Study: 34800701

Group type: EXPERIMENTAL
Intervention: Nivolumab alone or in combination with ipilimumab
Number of subjects: 44